Delineate
Agents for Accelerated Clinical Trial Design
Delineate is a company in b2b based in Boston, MA, USA; Remote.
Profile
Delineate is building AI agents to design better clinical trials faster.
This is a $10B dollar market, where saving even 1 day along the process is equal to $1-5M in revenue potential.
We process existing clinical trial research into specialized datasets saving scientists months of effort.
Delineate is working with two of the largest pharmaceutical companies. With one of our customers, we are helping them get to the next phase of trials faster by creating the largest dataset on a drug class ever constructed.
Delineate is positioned in b2b, a segment that rewards a clear, focused offering.
The company is recorded as being based in Boston, MA, USA; Remote.
It is recorded at the Winter 2025 stage.
The company reports a headcount in the 20 range.
Directory analysis
Delineate builds AI agents that accelerate clinical trial design by processing existing research into specialized datasets, saving scientists months of effort. The company targets the $10B clinical trial design market, partnering with major pharmaceutical firms to speed progression to later trial phases.
Positioning: By automating data curation and trial design, Delineate positions itself as a technology partner for large pharma seeking to reduce time‑to‑market. Its focus on AI‑driven datasets could offer significant cost savings, though the market remains competitive with other clinical trial optimization tools.
Note: Delineate offers AI agents for faster clinical trial design, targeting large pharmaceutical clients.
Auto-generated directory analysis from public data · updated 9 Oct 2026. Informational only, not investment advice.
| Sector | B2B |
|---|---|
| Headquarters | Boston, MA, USA; Remote |
| Country | USA; Remote |
| Employees | 20 |
| Stage | Winter 2025 |
Website: delineate.pro
Browse related
Create a free account